Cost-effectiveness of rotavirus vaccination in Mozambique.

ABSTRACT:

Introduction

Rotavirus is one of the most common cause of severe gastroenteritis in children, with the largest mortality burden in low- and middle-income countries. To prevent rotavirus gastroenteritis, Mozambique introduced ROTARIX® vaccine in 2015, however, its cost-effectiveness has never been established in the country. In 2018, additional vaccines became available globally. This study estimates the cost-effectiveness of the recently introduced ROTARIX in Mozambique and compares the cost-effectiveness of ROTARIX®, ROTAVAC®, and ROTASIIL® to inform future use.

Methods

We used a decision-support model to calculate the potential cost-effectiveness of vaccination with ROTARIX compared to no vaccination over a five-year period (2016-2020) and to compare the cost-effectiveness

SUBMITTER: Lourenco Guimaraes E 

PROVIDER: S-EPMC9421418 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature